Trials / Completed
CompletedNCT04876300
MEDAM (Menopur Retrospective Data prograM)
Predicting the Cumulative Live Birth Rate Further Ovarian Stimulation by Highly Purified Human Menotropin HP-hMG. A Multicentre, Retrospective Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 11,488 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years – 42 Years
- Healthy volunteers
- Not accepted
Summary
French, non-interventional, retrospective, multicentric analysis of patients who have undergone a controlled ovarian stimulation (COS) for in-vitro fertilization (IVF)/ intracytoplasmic sperm injection (ICSI). The main objective is to determine the cumulative live birth rate with highly purified menotropin (HP-hMG) which is defined as the occurrence of live birth per started COS, further to transfer of fresh and frozen embryos generated from the same COS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study will take place. |
Timeline
- Start date
- 2021-11-04
- Primary completion
- 2021-11-30
- Completion
- 2021-11-30
- First posted
- 2021-05-06
- Last updated
- 2022-01-25
Locations
10 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04876300. Inclusion in this directory is not an endorsement.